Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

ctive DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there will be an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- A novel combination of microscopy ... of Energy,s Oak Ridge National Laboratory an unprecedented look ... unusual physical and electrochemical properties. , The research ... affects the surface of a perovskite manganite, a complex ... new avenue to understand surface behavior could benefit researchers ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... and scale of EDS services allow Bristol-Myers Squibb to ... focus on core biopharmaceutical business, ... million information technology (IT) services contract that,calls for EDS to ... scope and scale will allow the company to,improve productivity so ...
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE) announced today that ... of Finance and Chief Financial Officer., Jim Hitchin ... many years of,experience in public medical device, manufacturing and ... 25 years ago. With a graduate,degree in accounting, he ...
... Dec. 10 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... identification of cancer, today announced that two,U.S. Patents, ... granted,to the Company by the United States Patent ... our on-going commitment to broadening,and protecting our intellectual ...
Cached Biology Technology:EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 2EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 3Jim Dorst Joins SpectraScience as CFO 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 3
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... 45% on average over a 35 year period in ... the impact of humans on declining animal numbers. This ... as insects, spiders, crustaceans, slugs and worms bring to ... crops, decomposition for nutrient cycling, water filtration and human ... and led by UCL, Stanford and UCSB, focused on ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... working in College of Life Science, Zhejiang University, has ... CpG island has a parental differentially methylated region (DMR). ... imprinting exists in lower vertebrates and genomic imprinting should ... mammals. The study is reported in volume 54 (Issue ...
... A team of University of Oregon biologists, using fruit ... specific cells, opening a new window on how gene ... While DNA (deoxyribonucleic acid) provides an identical genetic blueprint ... that turn protein molecules on and off in different ...
... is the latest American Chemical Society (ACS) Weekly PressPac ... from ACS, 34 peer-reviewed journals and Chemical & Engineering ... Society as the source for this information. ... melamine-adulterated food , Journal of Agricultural and Food ...
Cached Biology News:The evolutionary foundation of genomic imprinting in lower vertebrates 2New tool isolates RNA within specific cells 2American Chemical Society's Weekly PressPac -- May 13, 2009 2American Chemical Society's Weekly PressPac -- May 13, 2009 3American Chemical Society's Weekly PressPac -- May 13, 2009 4American Chemical Society's Weekly PressPac -- May 13, 2009 5American Chemical Society's Weekly PressPac -- May 13, 2009 6American Chemical Society's Weekly PressPac -- May 13, 2009 7American Chemical Society's Weekly PressPac -- May 13, 2009 8American Chemical Society's Weekly PressPac -- May 13, 2009 9American Chemical Society's Weekly PressPac -- May 13, 2009 10
hnRNP U (H-94)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Biology Products: